Adrian Rawcliffe, Chief Executive Officer at Adaptimmune Therapeutics PLC (ADAP), sold 2,536 shares at $1.97 ($5K) on 2022-09-01, disclosed to the SEC on 2022-09-01.
Open-market sale of $5k ADAP by Chief Executive Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| WVE | SELL | 2025-11-14 | $219K | — | Filing → |
| ADAP | SELL | 2025-01-17 | $18K | — | Filing → |
| ADAP | SELL | 2025-01-15 | $35K | — | Filing → |